Pediatric Eczema Treatment Across Skin Colors: What the PEDISTAD Registry Observed

Dr. Arsy Editorial Team · November 9, 2026

Clinical presentation and treatment experience can differ across skin tones, while research representation has often been uneven. A four-year PEDISTAD registry analysis examined systemic-treatment outcomes in 314 White and 186 non-White children younger than 12 with moderate-to-severe atopic dermatitis.^[2]

Observed changes across treatment groups

EASI improved in both skin-color groups. Observed EASI changes with dupilumab, methotrexate and cyclosporine were 13.6, 8.2 and 9.2 points in non-White children, and 14.2, 10.1 and 4.5 points in White children. Itch and quality-of-life improvements were particularly evident with dupilumab in both groups.^[2]

Why this is not a randomized race comparison

Registries reflect clinical choices. Children receiving different treatments may differ in severity, age, previous therapy, access and comorbidities. Broad “White” and “non-White” categories also combine diverse ancestry and skin tones. The study can describe observed patterns but cannot prove one drug is superior for every child or that race itself causes a response difference.

Better assessment requires better visibility

Erythema may look different on darker skin, and severity instruments can miss or misclassify color changes. Clinicians should assess texture, swelling, lichenification, excoriation, body surface area, itch, sleep and quality of life rather than relying on redness alone.^{[19][20][21][22]}

Questions for equitable care

• Has severity been assessed with both clinical and patient-reported measures?
• Are post-inflammatory pigment changes being separated from active inflammation?
• Does the family understand the treatment plan and monitoring?
• Are access, cost and follow-up barriers being addressed?

The registry supports improvement across groups while highlighting the need for inclusive enrollment and careful measurement. It should not be turned into a biological stereotype.^[9][10][11]

Product context

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not evaluated in the research above and is not a substitute for medical assessment or prescription care. Ask a pediatric clinician before using a specific product on a baby.

Related pediatric eczema research

• Does Childhood Eczema Lower Test Scores? A 3,641-Child Study Challenges Assumptions
• Eczema and Child Growth: What a 1,329-Child PEDISTAD Analysis Can—and Cannot—Say
• Dupilumab, Skin Proteins and the Microbiome: What TREATKids Added Beyond EASI
• Tapinarof Eczema Trials Across Skin Types: What the Subgroup Analysis Shows
• Related pediatric eczema guide
• Related pediatric eczema guide

Research and clinical references

1. Childhood atopic dermatitis and standardized testing: US birth cohort.
2. PEDISTAD systemic treatment outcomes by skin color.
3. PEDISTAD growth assessment in children under 12.
4. TREATKids clinical and molecular outcomes with dupilumab.
5. Tapinarof efficacy by race and Fitzpatrick skin type.
6. Atopic dermatitis and academic performance in Denmark and England.
7. Atopic dermatitis, sleep and cognition in US adults.
8. Eczema and educational attainment: systematic review.
9. Pediatric atopic dermatitis guideline.
10. AAP skin-directed management clinical report.
11. AAAAI/ACAAI atopic dermatitis guideline.
12. Dupilumab in children 6 months to younger than 6 years.
13. Dupilumab in children 6 to 11 years with severe atopic dermatitis.
14. Dupilumab in adolescents with atopic dermatitis.
15. Tapinarof ADORING phase 3 trials.
16. Long-term topical therapy in pediatric atopic dermatitis: ROAD study.
17. Atopic dermatitis and child height: systematic review.
18. Growth and nutritional status in children with atopic dermatitis.
19. Atopic dermatitis in skin of color: clinical considerations.
20. Racial and ethnic representation in atopic dermatitis trials.
21. Core outcome instruments for atopic eczema.
22. EASI validation across skin types.
23. Patient-Oriented Eczema Measure validation in children.
24. Atopic dermatitis quality-of-life burden in children and families.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.